Please login to the form below

Procoralan

This page shows the latest Procoralan news and features for those working in and with pharma, biotech and healthcare.

The drug has been marketed for years in Europe by privately-held Servier under the Procoralan brand name.

FDA clears Amgen's Corlaner for heart failure

Corlaner is already on the market in Europe - where it is sold by privately held Servier as Procoralan and was approved to treat stable angina in 2005 and CHF in 2012.
Amgen gets priority review for chronic heart failure hope

require additional clinical trials, despite the fact that the drug is already sold (as Servier's Procoralan) for CHF and also stable angina in Europe.
Amgen throws its hat into the cholesterol antibody ring

Procoralan (ivabradine) from Servier in July.
Amgen drug misses endpoint in acute heart failure trial

This was part of a deal that involved Amgen obtaining US rights to Servier's chronic heart failure drug Procoralan (ivabradine).
Amgen buys US rights to Servier’s Procoralan

Amgen buys US rights to Servier’ s Procoralan. Also obtains option to develop S38844 while Servier has option to commercialise omecamtiv mecarbil in Europe. ... The major drug involved in the deal is Servier's Procoralan (ivabradine), which Amgen has

More from news
Approximately 2 fully matching, plus 13 partially matching documents found.

Heart failure therapy embarks on a new era

has been sold for HF in Europe as Procoralan/Corlenter by originator Servier since 2012.
Deal Watch table for July 2013

100. ‡‡ Servier / Amgen . Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2).
Pharma deals during July 2013

Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates. ... Amgen is paying $50m upfront for US rights to

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Add my company

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Pharma’s isolated islands of innovation: With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit: What does it mean for the life science sector?...
The Holy Grail of HCP Access: This is the data you need to gain access....